OR WAIT null SECS
GSK will close the Sligo, Ireland skincare product manufacturing site by 2021.
GlaxoSmithKline (GSK) informed employees at its skincare product manufacturing site in Sligo, Ireland of a proposal to close the site, the company announced in an Aug. 16, 2018 statement. Under this proposal, which affects approximately 165 employees, the company would phase down production over three years, before decommissioning the site in the latter part of 2021.
Although the Sligo site has delivered significant improvements in cost and efficiency in recent years, demand for the products made at the site has not grown in line with previous expectations, the company explained. GSK’s other operations in Ireland, including manufacturing sites in Cork and Dungarvan and commercial operations in Dublin, are not affected by this proposal.